Jeff Zonder

795 total citations
14 papers, 391 citations indexed

About

Jeff Zonder is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Jeff Zonder has authored 14 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Jeff Zonder's work include Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). Jeff Zonder is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). Jeff Zonder collaborates with scholars based in United States, United Kingdom and Italy. Jeff Zonder's co-authors include Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Donna Reece, Karen Wells, Ashutosh Wechalekar, Rodney H. Falk, Howard Streicher, Heather Landau and Morie A. Gertz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Jeff Zonder

14 papers receiving 383 citations

Peers

Jeff Zonder

HEMAT

GENET

ONCOL

NEPHR

Irini Xilouri Greece

Salli Fennessey United States

Siyang Leng United States

Yoshitaka Sunami Japan

Ingrid I. van Gameren Netherlands

Tetsuichi Yoshizato Japan

Cesare Bergonzi Italy

Nobuyoshi Hanaoka Japan

Miriam Hobbs United States

J. Maciejewski United States

Irini Xilouri Greece

Jeff Zonder

238 ×0.7

208 ×1.4

HEMAT

119 ×1.0

GENET

123 ×1.1

ONCOL

27 ×0.3

NEPHR

Citations per year, relative to Jeff Zonder Jeff Zonder (= 1×) peers Irini Xilouri

Countries citing papers authored by Jeff Zonder

Since Specialization

Citations

This map shows the geographic impact of Jeff Zonder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Zonder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Zonder more than expected).

Fields of papers citing papers by Jeff Zonder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Zonder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Zonder. The network helps show where Jeff Zonder may publish in the future.

Co-authorship network of co-authors of Jeff Zonder

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Zonder. A scholar is included among the top collaborators of Jeff Zonder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Zonder. Jeff Zonder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Seymour, Erlene, Yiwei Li, Amro Aboukameel, et al.. (2020). Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study. Blood. 136(Supplement 1). 11–12. 1 indexed citations

Patel, Krish, Radhakrishnan Ramchandren, Michael B. Maris, et al.. (2020). Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood. 136(Supplement 1). 46–47. 14 indexed citations

Dispenzieri, Angela, Jeff Zonder, James E. Hoffman, et al.. (2020). Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database. Blood. 136(Supplement 1). 4–5. 1 indexed citations

Jasielec, Jagoda, Jeff Zonder, Benjamin A. Derman, et al.. (2020). Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study. Blood. 136(Supplement 1). 50–50. 4 indexed citations

Comenzo, Ray, Efstathios Kastritis, Mathew S. Maurer, et al.. (2019). S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN‐IN RESULTS OF ANDROMEDA. HemaSphere. 3(S1). 392–392. 10 indexed citations

Auclair, Daniel, Carol Mansfield, Ajai Chari, et al.. (2017). Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach. Blood. 130. 5662–5662. 2 indexed citations

Comenzo, Raymond L., Donna Reece, Giovanni Palladini, et al.. (2012). Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 26(11). 2317–2325. 267 indexed citations

Vij, Ravi, Thomas G Martin, Jeff Zonder, et al.. (2010). Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.. Journal of Clinical Oncology. 28(15_suppl). 8128–8128. 19 indexed citations

Shah, Jatin J., et al.. (2010). Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology. 28(15_suppl). 8132–8132. 1 indexed citations

10.

Gasparetto, Cristina, Vaishali Sanchorawala, Howard R. Terebelo, et al.. (2010). Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis.. Journal of Clinical Oncology. 28(15_suppl). 8024–8024. 10 indexed citations

11.

Zonder, Jeff, John J. Crowley, Vanessa Bolejack, et al.. (2008). A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. Journal of Clinical Oncology. 26(15_suppl). 8521–8521. 14 indexed citations

12.

Mohamed, Anwar N., et al.. (2007). Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. American Journal of Hematology. 82(12). 1080–1087. 31 indexed citations

13.

Richardson, Paul G., Andrzej Jakubowiak, J. Wolf, et al.. (2007). Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.. Blood. 110(11). 1170–1170. 14 indexed citations

14.

Hussein, Mohamad A., Andrzej Jakubowiak, Vanessa Bolejack, et al.. (2006). S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) Maintenance: A Phase II Trial of the Southwest Oncology Group.. Blood. 108(11). 3088–3088. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact